Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections?

Annals of Pharmacotherapy

Volumn 30, Issue 7-8, 1996, Pages 811-818

  Nagata, Maureen P ^a,b   Gentry, Chris A ^a,c   Hampton, Edward M ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Champlain Valley Phys's Hosp M   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; AMMONIUM CHLORIDE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; CREATININE; FLUCYTOSINE; INULIN; LIPOSOME; RIFAMPICIN; STEROID; TRIAZOLE DERIVATIVE;

ANEMIA; CANDIDIASIS; CLINICAL TRIAL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOPHLEBITIS; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 0030015531     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000720     Document Type: Review

References (58)

1. Bindschadler DD, Bennett JE. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis 1969;120:427-36.
2. Fields BTJ, Bates JH. Amphotericin B serum concentrations during therapy. Appl Microbiol 1970;19:955-9.
3. Feldman HA, Hamilton JD, Gutman RA. Amphotericin B therapy in an anephric patient. Antimicrob Agents Chemother 1973;4:302-5.
4. Louria DB, Feder N, Emmons CW. Amphotericin B in experimental histoplasmosis and cryptococcosis. In: Antibiotics annual 1956-1957. New York: American Encyclopedia, Inc., 1957:870-7.
5. Atkinson AJ, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978;13:271-6.
6. Chabot GG, Pazdur R, Valeriote FA, Baker LH. Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J Pharm Sci 1989;78:307-10.
7. Block ER, Bennett JE, Livoti LG, Klein WJ, MacGregor RR, Henderson L. Flucytosine and amphotericin B: hemodialysis effects on plasma concentrations and clearance. Ann Intern Med 1974;80:613-7.
8. Morgan DJ, Ching MS, Raymond K, Bury RW, Mashford ML, Kong B, et al. Elimination of amphotericin B in impaired renal function. Clin Pharmacol Ther 1983;34:248-53.
9. Christiansen KJ, Bernard EM, Gold JWM, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis 1985;152:1037-43.
10. Collette N, Van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 1989;33:362-8.
11. Polak A. Pharmacokinetics of amphotericin B and flucytosine. Postgrad Med J 1979;55:667-70.
12. Drutz DJ, Spickard A, Rogers DE, Koenig MG. Treatment of disseminated mycotic infections. Am J Med 1968;45:405-18.
13. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
14. Craven PC, Ludden TM, Drutz DJ, Rogers W, Haegele KA, Skrdlant HB. Excretion pathways of amphotericin B. J Infect Dis 1979;149:329-41.
15. Louria DB. Some aspects of the absorption, distribution and excretion of amphotericin B in man. Antibiot Med Clin Ther 1958;5:295-301.
16. Graybill JR, Craven PC. Antifungal agents used in systemic mycoses. Drugs 1983;25:41-62.
17. Mandell GL, Douglas RG, Bennett JE. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1990;199-212,401-10, 2289-311.
18. Gorbach SL, Bartlett JG, Blacklow NR. Infectious diseases. Philadelphia: WB Saunders, 1992;153-60,307-13,1887-95.
19. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility testing. Clin Microbiol Rev 1993;6:367-81.
20. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995;39:40-4.
21. Anaissie EJ, Karyotakis NC, Hachem R, Dignani MC, Rex JH, Paetznick V. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis 1994;170:384-9.
22. Stiller RL, Bennett JE, Scholer HJ, Wall M, Polak A, Stevens DA. Correlation of in vitro susceptibility test results with in vivo response. J Infect Dis 1983;147:1070-7.
23. Polak A, Odds FC, Ludin E, Scholer HJ. Correlation of susceptibility test results in vitro with response in vivo: ketoconazole therapy in a systemic candidiasis model. Chemotherapy 1985;31:395-404.
24. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B resistant yeast infection in severely immunocompromised patients. Am J Med 1988;84:826-32.
25. Bryce EA, Roberts FJ, Sekhon AS, Coldman AJ. Yeast in blood cultures: evaluation of factors influencing outcome. Diagn Microbiol Infect Dis 1992;15:233-7.
26. Graybill JR. Is there a correlation between serum antifungal drug concentration and clinical outcome? J Infect Dis 1994;28:17-24.
27. Clements JS, Peacock JE. Amphotericin B revisited: reassessment of toxicity. Am J Med 1990;88:5-22N-5-27N.
28. Bell NH, Andriole VT, Sabesin SM, Utz JP. On the nephrotoxicity of amphotericin B in man. Am J Med 1962;33:64-9.
29. Wertlake PT, Butler WT, Hill GJ, Utz JP. Nephrotoxic tubular damage and calcium deposition following amphotericin B therapy. Am J Pathol 1963;43:449-53.
30. Winn WA. Coccidioidomycosis and amphotericin B. Med Clin North Am 1963;47:1137-48.
31. Butler WT, Bennett JE, Alling DW, Wertlake PT, Utz JP, Hill GJ. Nephrotoxicity of amphotericin B. Ann Intern Med 1964;61:175-87.
32. McCurdy DK, Frederic M, Elkinton JR. Renal tubular acidosis due to amphotericin B. N Engl J Med 1968;278:124-31.
33. Miller RP, Bates JH. Amphotericin B toxicity. Ann Intern Med 1969;71: 1089-95.
34. Patterson RM, Ackerman GL. Renal tubular acidosis due to amphotericin B nephrotoxicity. Arch Intern Med 1971;127:241-4.
35. Burgess JL, Birchall R. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am J Med 1972;53:77-84.
36. Solomkin JS, Flohr A, Simmons RL. Candida infections in surgical patients. Ann Surg 1982;195:177-85.
37. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst WM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
38. Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host. Am J Med 1981;71:363-70.
39. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992;14(suppl 1):S120-5.
40. Sternberg TH, Wright ET, Oura M. A new antifungal antbiotic, amphotericin B. In: Antibiotics annual 1955-1956. New York: Medical Encyclopedia, Inc., 1956:566-73.
41. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
42. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988;108:88-100.
43. Haron E, Feld R, Tuffnell P, Patterson B, Hasselback R, Matlow A. Hepatic candidiasis: an increasing problem in immunocompromised patients. Am J Med 1987;83:17-26.
44. Janknegt R, De Marie S, Bakker-Woudenberg IAJM, Crommelin DJA. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992;23:279-91.
45. Andriole VT, Kravetz HM, Roberts WC, Utz JP. Candida endocarditis. Am J Med 1962;32:251-85.
46. Moyer DV, Edwards JE Jr. Fungal endocarditis. In: Kaye D, ed. Infective endocarditis. New York: Raven Press, Ltd., 1995:299-312.
47. Tasjian LS, Abramson JS, Peacock JE. Focal hepatic candidiasis: a distinct clinical variant of candidiasis in immunocompromised patients. Rev Infect Dis 1984;6:689-703.
48. Medoff G. Controversial areas in antifungal chemptherapy: short-course and combination therapy with amphotericin B. Rev Infect Dis 1987;9: 403-7.
49. Medoff GM, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med 1980;302:145-55.
50. Meyer RD. Current role of therapy with amphotericin B. Clin Infect Dis 1992;14(suppl 1):S154-60.
51. Edwards JE, Filler SG. Current strategies for treating invasive candidiasis: emphasis on infections in neutropenic patients. Clin Infect Dis 1992; 14(suppl 1):S106-13.
52. Meunier F. Candidiasis. Eur J Clin Microbiol infect Dis 1989;8:438-47.
53. Rosemurgy AS, Drost TF, Murphy CG, Kearney RE, Albrink MH. Treatment of candidosis in severely injured adults with short-course, low-dose amphotericin B. J Trauma 1990;30:1521-3.
54. Stamm AM, Dismukes WE. Current therapy of pulmonary and disseminated fungal diseases. Chest 1983;83:911-7.
55. Amphotericin B. In: McEvoy GK, ed. AHFS 95 drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1995: 73-6.
56. Package insert. Abelcet (liposomal amphotericin B). Princeton, NJ: The Liposome Company, 1995.
57. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991;35:615-21.
58. Harrison LH, Stevens DA. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B sulfate colloidal dispersion. Antimicrob Agents Chemother 1992;36:486-8.